Novavax’s Covid-19 vaccine nearly 90% effective in U.K. study, much less in South Africa

The results make its candidate “the first vaccine to demonstrate not only high clinical efficacy against Covid-19 but also significant clinical efficacy against both the rapidly emerging U.K. and South Africa variants,” Novavax President and CEO Stanley Erck in a statement.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.